Semaglutide should be first-line option for diabetic CKD, doctors say
The GLP-1 receptor agonist cuts the risk of major kidney disease events compared with placebo, research shows.
Semaglutide should be a first-line treatment option for adults with diabetic chronic kidney disease and albuminuria, say renal specialists.
It follows a landmark Australian-led trial, funded by Novo Nordisk, which showed the GLP-1 receptor agonist (GLP-1 RA) cut the risk of major kidney events — including kidney failure and death — by 24% compared with placebo.
